Stephanie L Graff, MD, FACP
Director of Breast Oncology
Lifespan Cancer Institute
Dr. Stephanie Graff explains details and results of the landmark Destiny Breast 04 Trial – which has changed the way that doctors treat patients with HER2-positive metastatic breast cancer, and helped determine if patients can be treated differently with early diagnosis. The Trastuzumab Deruxtecan T-DXd) (brand name: Enhertu) drug finds HER2-positive breast cancer in a targeted fashion and delivers chemotherapy to it, known as “smart chemo.”
Research results received a standing ovation at a plenary session presentation before 42,000 oncologists at the American Society of Clinical Oncology annual meeting in Chicago.
Topics discussed include Destiny Breast 06 and 07 Trials, various stages of cancer, the role of cellular protein and the hormone estrogen, how often T-DXd is delivered intravenously, its side effects and availability, and how participation in clinical drug trials should be the first step for patients after cancer diagnosis. Dr. Graff also talks about her Woman Disruptor of the Year award in the field of medical oncology and her Brown Hematology/Oncology Fellowship Mentor of the Year Award.
Special guest in the studio is Dr. Stephanie Haddad, a second-year Brown Internal Medicine resident interested in oncology with experience as a breast cancer clinical trial research coordinator.
Brown Medicine is pleased to be on the forefront of cutting-edge science and exciting research such as this particular study.
